# A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

> **NCT03126097** · PHASE1 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64155806 150 mg
- **DRUG:** Ethinylestradiol/drospirenone 0.02 mg/3 mg
- **DRUG:** COCP Placebo

## Key facts

- **NCT ID:** NCT03126097
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-13
- **Primary completion:** 2017-05-26
- **Final completion:** 2017-05-26
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Study stopping rules were met.
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126097, "A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03126097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*